Prevention guidelines cholesterol
Published on: Mar 4, 2016
Transcripts - Prevention guidelines cholesterol
10 Points to Remember on the Treatment of
Blood Cholesterol to Reduce
Atherosclerotic Cardiovascular Risk in
Summary Prepared by Melvyn Rubenfire, MD
The 2013 ACC/AHA Expert Panel included all 16 members of
the National Heart, Lung, and Blood Institute Adult Treatment
Panel (ATP) IV, and the document review included 23 expert
reviewers and representatives of federal agencies. The expert
panel recommendations arose from careful consideration of
an extensive body of higher quality evidence derived from
randomized controlled trials (RCTs), and systematic reviews
and meta-analyses of RCTs.
Through a rigorous process, four groups of individuals were
identified for whom an extensive body of RCT evidence
demonstrated a reduction in atherosclerotic cardiovascular
disease (ASCVD) events (including coronary heart disease
[CHD], cardiovascular deaths, and fatal and nonfatal strokes)
with a good margin of safety from statin therapy:
Point 2 (cont.)
Four Statin Benefit Groups:
•Individuals with clinical ASCVD (acute coronary syndromes, or a history of
MI, stable or unstable angina, coronary or other arterial revascularization,
stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic
origin ) without New York Heart Association (NYHA) class II-IV heart failure
or receiving hemodialysis.
•Individuals with primary elevations of low-density lipoprotein cholesterol
(LDL-C) ≥190 mg/dl.
•Individuals 40-75 years of age with diabetes, and LDL-C 70-189 mg/dl
without clinical ASCVD.
•Individuals without clinical ASCVD or diabetes, who are 40-75 years of age
with LDL-C 70-189 mg/dl, and have an estimated 10-year ASCVD risk of
7.5% or higher.
Individuals in the fourth group can be identified by
using the new Pooled Cohort Equations for ASCVD
risk prediction, developed by the Risk Assessment
Lifestyle modification (i.e., adhering to a heart healthy diet,
regular exercise habits, avoidance of tobacco products, and
maintenance of a healthy weight) remains a critical
component of health promotion and ASCVD risk reduction,
both prior to and in concert with the use of cholesterol-
lowering drug therapies.
There is no evidence to support continued use of specific LDL-
C and/or non–high-density lipoprotein cholesterol (non–HDL-
C) treatment targets. The appropriate intensity of statin
therapy should be used to reduce risk in those most likely to
benefit. Nonstatin therapies, whether alone or in addition to
statins, do not provide acceptable ASCVD risk reduction
benefits compared to their potential for adverse effects in the
routine prevention of ASCVD.
This guideline recommends use of the new
Pooled Cohort Equations to estimate 10-year
ASCVD risk in both white and black men and
women. By more accurately identifying higher
risk individuals for statin therapy, the guideline
focuses statin therapy on those most likely to
benefit. It also indicates, based on RCT data,
those high-risk groups that may not benefit.
No recommendations are made to inform treatment decisions
in selected individuals who are not included in the four statin
benefit groups. In these individuals whose 10-year risk is
<7.5% or when the decision is unclear, other factors including
family history of premature ASCVD, LDL-C >160 mg/dl, high-
sensitivity C-reactive protein ≥2 mg/dl, coronary calcium score
≥300 Agatston units or ≥75th
percentile for age, sex, ethnicity,
and ankle-brachial index <0.9, or elevated lifetime risk of
ASCVD may be used to enhance the treatment decision
High-intensity statin therapy is defined as a daily dose
that lowers LDL-C by ≥50% and moderate-intensity by
30% to <50%. All patients with ASCVD who are age
≤75 years, as well as patients >75 years, should
receive high-intensity statin therapy; or if not a
candidate for high-intensity, should receive moderate-
intensity statin therapy.
Those with an LDL-C ≥190 mg/dl should receive high-intensity
or moderate-intensity statin therapy, if not a candidate for
high-intensity statin therapy. Addition of other cholesterol-
lowering agents can be considered to further lower LDL-C.
Diabetics with a 10-year ASCVD ≥7.5% should receive high-
intensity statins and <7.5% moderate-intensity statin therapy.
Persons 40-75 years with a ≥7.5% 10-year ASCVD risk should
receive moderate- to high-intensity statin therapy.
The following are no longer considered
appropriate strategies: treat to target, lower is
best. The new GL recommends: treat to level
of ASCVD risk, based upon estimated 10-
year or lifetime risk of ASCVD. The guidelines
provided no recommendations for initiating or
discontinuing statins in NYHA class II-IV
ischemic systolic heart failure patients or
those on maintenance hemodialysis.
In primary prevention, the cholesterol guidelines recommend
not only the risk calculation, but also the physician–patient
review of the risk and the decision to take a statin. It is
important to realize that the ASCVD risk calculator is heavily
influenced by age. A 65-year-old man and a 71-year-old
woman with optimal risk factors have a >7.5% 10-year risk.
This is where physician judgment, statin safety issues, and a
consideration of patient preferences can inform this decision.
Prescription of a statin is not automatic, but part of a
comprehensive approach to risk reduction that begins with the
use of the ASCVD risk calculator and with the assumption that
the physician is addressing each of the modifiable risk factors.